Medicaid URA cap removal: How manufacturer operations and the drug discount landscape could be impacted

The dynamic political landscape surrounding drug pricing is sure to present changes and challenges for drug manufacturers in 2021, especially in the area of drug discounts. One impactful change is the removal of the Medicaid Unit Rebate Amount cap, which aims to create a painful financial disincentive for manufacturers who have increased a drug’s price faster than the rate of inflation. The Congressional Budget Office has scored this provision as a way to reduce direct spending in Medicaid by $15.9B in the next decade. However, removing this cap has other implications, especially for drug manufacturers.

Listen to this webinar to learn how this change may impact your 340B strategy, how you can operationalize the processing of Medicaid rebate claims, and how to navigate this developing situation to effectively manage your drug discount programs.

<span class="blog-button">Download webinar presentation</span>

‍